ストックスクリーナーアプリを入手
4.08
4.88%
0.19
前日終値:
$3.89
開ける：
$3.93
24時間の取引高:
999.10K
Relative Volume:
2.58
時価総額：
$250.58M
収益：
$45.15M
当期純損益:
$-39.23M
株価収益率:
-2.2307
EPS:
-1.829
ネットキャッシュフロー:
$-18.93M
1週間 パフォーマンス:
+12.09%
1か月 パフォーマンス:
+34.65%
6か月 パフォーマンス:
-43.96%
1年 パフォーマンス:
-24.16%
1日の値動き範囲:
$3.84
$4.285
1週間の範囲:
$3.56
$4.455
52週間の値動き範囲:
$2.20
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
名前
Trisalus Life Sciences Inc
セクター
電話
415 336 8917
住所
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.08 | 250.58M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-13 | 開始されました | Lake Street | Buy |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-11-11 | 開始されました | ROTH MKM | Buy |
| 2024-10-25 | 開始されました | Northland Capital | Outperform |
| 2024-09-16 | 開始されました | Oppenheimer | Outperform |
| 2024-05-30 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Trisalus Life Sciences Inc (TLSI) 最新ニュース
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc.TLSI - PR Newswire
TriSalus Life Sciences Inc (TLSIW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TriSalus Life Sciences Inc (TLSIW) Institutional Confidence - TradingKey
TriSalus Life Sciences Inc (TLSIW) Valuation: PE, PB & Fair Value Analysis - TradingKey
TriSalus Life Sciences Inc (TLSIW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TriSalus Life Sciences Inc (TLSIW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TriSalus Life Sciences Inc (TLSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TriSalus Life Sciences Inc (TLSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TriSalus Life Sciences Inc (TLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TriSalus Life Sciences Inc (TLSI) Institutional Confidence - TradingKey
TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TriSalus Life Sciences Inc (TLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TriSalus Life Sciences Inc (TLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TriSalus Life Sciences Inc (TLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
TriSalus Life Sciences Inc (TLSIW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TriSalus Life Sciences Inc (TLSIW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TriSalus Life Sciences Inc (TLSIW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Richard Marshall Accepts New Role at TriSalus Life Sciences - Medical Product Outsourcing
TriSalus Life Sciences Warrants (TLSIW) Hold Steady Near Support in Quiet TradingAndrews Pitchfork - newsline.com
TLSI Q1 2026 Earnings: EPS Surprise of 118.86% Drives Stock HigherAnalyst Drop Coverage - newsline.com
TriSalus Life Sciences (TLSI) Q1 2026 Earnings: Surprise Profitability as EPS Beats Estimates by 118.86% - newsline.com
TLSI News | TRISALUS LIFE SCIENCES INC (NASDAQ:TLSI) - ChartMill
TriSalus Life Sciences (TLSI) Gains 2.88% as Stock Approaches Key Resistance LevelWave Extension - newsline.com
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer - Stock Titan
TriSalus Life Sciences Inc. (TLSI) Q1 2026 Earnings: Strong EPS Surprise Driven by Operational ProgressFree Cash Flow Trends - newsline.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TriSalus Life Sciences, Inc. (TLSI) And Encourages Shareholders to Reach Out - ACCESS Newswire
TLSI INVESTOR ALERT: Holzer & Holzer, LLC Investigation of TriSalus Life Sciences, Inc. - GlobeNewswire
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-06-03 | Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Shareholders to Inquire about Securities Investigation | NDAQ:TLSI | Press Release - Stockhouse
TSLI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law Firm - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (TLSI) And Encourages Investors to Connect - ACCESS Newswire
TLSI Q1 2026 Earnings: Surprise EPS Beat Despite No Revenue, Stock DeclinesMargin Guidance - newsline.com
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2026-06-01 | Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Stockholders to Inquire about Securities Investigation | NDAQ:TLSI | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
TLSI Q1 2026 Earnings: Surprise Profit Beats Analyst Estimates, Shares RallySurprise Factor Analysis - newsline.com
Number of shareholders of TriSalus Life Sciences, Inc. – NASDAQ:TLSI - TradingView
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TriSalus Life Sciences Q1 2026 Earnings: Surprise EPS Profit of $0.03 Beats Estimates by 118.9%Forward Guidance Trends - newsline.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (TLSI) And Encourages Stockholders to Connect - ACCESS Newswire
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TriSalus Life Sciences, Inc. (TLSI) Investigation: Bronstein, Gew - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TriSalus Life Sciences, Inc. (TLSI) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
TriSalus Life Sciences (TLSI) Falls Over 5% as Stock Tests Key Support Near $3.10Stop Hunt - The Legal Advocate
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Sciences, Inc. (TLSI) Investors to Inquire about Securities Investigation - ACCESS Newswire
Investigation launched into TriSalus Life Sciences after Q1 revenue misses estimates and cuts full-year guidance - Pluang
TLSI Q1 2026 Earnings: EPS Surprises Positively Despite No Revenue, Stock DeclinesProfit Warning Alert - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (RLSI) And Encourages Stockholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life - The National Law Review
Trisalus Life Sciences Inc (TLSI) 財務データ
収益
当期純利益
現金流量
EPS
Trisalus Life Sciences Inc (TLSI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Wahlstrom Mats | Director |
May 15 '26 |
Buy |
2.53 |
60,000 |
151,800 |
147,555 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
410,000 |
1,025,000 |
1,240,722 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
200,000 |
500,000 |
399,698 |
| Szela Mary T | CEO and President |
May 15 '26 |
Buy |
2.59 |
39,682 |
102,776 |
1,065,215 |
| Patience David | Chief Financial Officer |
May 15 '26 |
Buy |
2.43 |
7,100 |
17,253 |
275,757 |
| Gordon Gary B. | Director |
May 15 '26 |
Buy |
2.46 |
10,000 |
24,600 |
72,510 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 12 '26 |
Sale |
4.09 |
1,772 |
7,247 |
97,637 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 11 '26 |
Sale |
4.13 |
1,162 |
4,799 |
99,409 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 16 '26 |
Sale |
4.12 |
273 |
1,125 |
97,364 |
| Cox Bryan F. | Chief of Research |
Mar 12 '26 |
Sale |
4.09 |
1,467 |
6,000 |
163,994 |
0.93%
大文字化:
|
ボリューム (24 時間):